Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

SF3B1 mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

SF3B1 mutation	Myelodysplastic Syndrome	SF3B1 mutation	Myelodysplastic Syndrome	luspatercept-aamt Sensitive: A2 - Guideline luspatercept-aamt Sensitive : A2	luspatercept-aamt Sensitive: A2 - Guideline luspatercept-aamt Sensitive : A2
SF3B1 mutation	Chronic Lymphocytic Leukemia	SF3B1 mutation	Chronic Lymphocytic Leukemia	ofatumumab Resistant: B - Late Trials ofatumumab Resistant : B	ofatumumab Resistant: B - Late Trials ofatumumab Resistant : B
SF3B1 mutation	Chronic Lymphocytic Leukemia	SF3B1 mutation	Chronic Lymphocytic Leukemia	chlorambucil Resistant: B - Late Trials chlorambucil Resistant : B	chlorambucil Resistant: B - Late Trials chlorambucil Resistant : B
SF3B1 mutation	Chronic Lymphocytic Leukemia	SF3B1 mutation	Chronic Lymphocytic Leukemia	obinutuzumab Resistant: B - Late Trials obinutuzumab Resistant : B	obinutuzumab Resistant: B - Late Trials obinutuzumab Resistant : B
SF3B1 mutation	Acute Myelogenous Leukemia	SF3B1 mutation	Acute Myelogenous Leukemia	CA-4948 Sensitive: C2 – Inclusion Criteria CA-4948 Sensitive : C2	CA-4948 Sensitive: C2 – Inclusion Criteria CA-4948 Sensitive : C2
SF3B1 mutation	Myelodysplastic Syndrome	SF3B1 mutation	Myelodysplastic Syndrome	CA-4948 Sensitive: C2 – Inclusion Criteria CA-4948 Sensitive : C2	CA-4948 Sensitive: C2 – Inclusion Criteria CA-4948 Sensitive : C2
SF3B1 mutation	Acute Myelogenous Leukemia	SF3B1 mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3
SF3B1 mutation	Acute Myelogenous Leukemia	SF3B1 mutation	Acute Myelogenous Leukemia	venetoclax Resistant: C3 – Early Trials venetoclax Resistant : C3	venetoclax Resistant: C3 – Early Trials venetoclax Resistant : C3
SF3B1 mutation	Myelodysplastic Syndrome	SF3B1 mutation	Myelodysplastic Syndrome	lenalidomide Resistant: C3 – Early Trials lenalidomide Resistant : C3	lenalidomide Resistant: C3 – Early Trials lenalidomide Resistant : C3
SF3B1 mutation	Acute Myelogenous Leukemia	SF3B1 mutation	Acute Myelogenous Leukemia	venetoclax + ABBV 075 Sensitive: C3 – Early Trials venetoclax + ABBV 075 Sensitive : C3	venetoclax + ABBV 075 Sensitive: C3 – Early Trials venetoclax + ABBV 075 Sensitive : C3
SF3B1 mutation	Chronic Lymphocytic Leukemia	SF3B1 mutation	Chronic Lymphocytic Leukemia	obinutuzumab + GS-9973 Sensitive: C3 – Early Trials obinutuzumab + GS-9973 Sensitive : C3	obinutuzumab + GS-9973 Sensitive: C3 – Early Trials obinutuzumab + GS-9973 Sensitive : C3
SF3B1 mutation	Chronic Lymphocytic Leukemia	SF3B1 mutation	Chronic Lymphocytic Leukemia	venetoclax Resistant: C3 – Early Trials venetoclax Resistant : C3	venetoclax Resistant: C3 – Early Trials venetoclax Resistant : C3
SF3B1 mutation	Chronic Myeloid Leukemia	SF3B1 mutation	Chronic Myeloid Leukemia	VE-821 Sensitive: D – Preclinical VE-821 Sensitive : D	VE-821 Sensitive: D – Preclinical VE-821 Sensitive : D
SF3B1 mutation	Melanoma	SF3B1 mutation	Melanoma	Immunotherapy Sensitive: D – Preclinical Immunotherapy Sensitive : D	Immunotherapy Sensitive: D – Preclinical Immunotherapy Sensitive : D